Gilead's price target raised

Investor's Business Daily

A JPMorgan analyst raised his price target on the biotech to $75 from $70 on Stribild, the company's new HIV medication. On Fri., Gilead (GILD) shares rose nearly 3% to close at a new high of 62.02 after Deutsche Bank analyst Robyn Karnauskas raised her price target on Gilead to 68 a share from 65. Shares rose 6.1% to 65.80. Jazz Pharmaceuticals (JAZZ) shares soared 14.9% to 55.29 after a federal court ruled largely in its favor. It's suing Roxane Laboratories over generic production of Xyrem, Jazz's narcolepsy medicine.

View Comments (0)